FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894594324> ?p ?o ?g. }

• W2894594324 endingPage "7" @default.
• W2894594324 startingPage "1" @default.
• W2894594324 abstract "After initially successful treatment of infantile spasms, the long-term cumulative risk of relapse approaches 50%, and there is no established protocol to mitigate this risk. Although vigabatrin may be an effective means to prevent relapse, there is little guidance as to ideal duration and dosage. Using a cohort of children with infantile spasms and tuberous sclerosis complex (TSC), we evaluated the potential association of post-response VGB treatment and the rate of infantile spasms relapse. Patients with infantile spasms and clinical response to vigabatrin were identified among a multicenter prospective observational cohort of children with TSC. For each patient we recorded dates of infantile spasms onset, response to vigabatrin, relapse (if any), and quantified duration and dosage of vigabatrin after response. Time to relapse as a function of vigabatrin exposure was evaluated using survival analyses. We identified 50 children who responded to VGB. During a median follow-up of 16.6 months (IQR 10.3-22.9), 12 (24%) patients subsequently relapsed after a median of 7.8 months (IQR 3.1-9.6). Relapse occurred after VGB discontinuation in four patients, and during continued VGB treatment in the remaining eight cases. In survival analyses, risk of relapse was unaffected by the presence or absence of VGB treatment (HR 0.31, 95%CI 0.01-28.4, P = 0.61), but weighted-average dosage was associated with marked reduction in relapse risk: Each 50 mg/kg/d increment in dosage was associated with 61% reduction in risk (HR 0.39, 95%CI 0.17 - 0.90, P = 0.026). This study suggests that the risk of infantile spasms relapse in TSC may be reduced by high-dose vigabatrin treatment." @default.
• W2894594324 created "2018-10-12" @default.
• W2894594324 creator A5001001811 @default.
• W2894594324 creator A5004499685 @default.
• W2894594324 creator A5008873914 @default.
• W2894594324 creator A5011802071 @default.
• W2894594324 creator A5021072194 @default.
• W2894594324 creator A5028623947 @default.
• W2894594324 creator A5032537143 @default.
• W2894594324 creator A5036008316 @default.
• W2894594324 creator A5044154502 @default.
• W2894594324 creator A5049445389 @default.
• W2894594324 creator A5053002960 @default.
• W2894594324 creator A5064059340 @default.
• W2894594324 creator A5066921588 @default.
• W2894594324 creator A5071430390 @default.
• W2894594324 creator A5073230151 @default.
• W2894594324 creator A5075514097 @default.
• W2894594324 creator A5075894817 @default.
• W2894594324 creator A5077316104 @default.
• W2894594324 creator A5079691093 @default.
• W2894594324 creator A5081010890 @default.
• W2894594324 creator A5088223126 @default.
• W2894594324 creator A5088980190 @default.
• W2894594324 date "2018-12-01" @default.
• W2894594324 modified "2023-10-14" @default.
• W2894594324 title "High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex" @default.
• W2894594324 cites W1573763499 @default.
• W2894594324 cites W1575745249 @default.
• W2894594324 cites W1594274983 @default.
• W2894594324 cites W1963519141 @default.
• W2894594324 cites W1966186739 @default.
• W2894594324 cites W1984389146 @default.
• W2894594324 cites W1997190808 @default.
• W2894594324 cites W2024975735 @default.
• W2894594324 cites W2037122149 @default.
• W2894594324 cites W2060806258 @default.
• W2894594324 cites W2064822478 @default.
• W2894594324 cites W2067672673 @default.
• W2894594324 cites W2083563713 @default.
• W2894594324 cites W2095185628 @default.
• W2894594324 cites W2125508519 @default.
• W2894594324 cites W2128250146 @default.
• W2894594324 cites W2133572298 @default.
• W2894594324 cites W2146082584 @default.
• W2894594324 cites W2164166856 @default.
• W2894594324 cites W2171386011 @default.
• W2894594324 cites W2193342048 @default.
• W2894594324 cites W2218896197 @default.
• W2894594324 cites W2281671491 @default.
• W2894594324 cites W2430250491 @default.
• W2894594324 cites W2552835369 @default.
• W2894594324 cites W2589631261 @default.
• W2894594324 cites W2594644573 @default.
• W2894594324 cites W2765508101 @default.
• W2894594324 doi "https://doi.org/10.1016/j.eplepsyres.2018.09.016" @default.
• W2894594324 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6347124" @default.
• W2894594324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30296632" @default.
• W2894594324 hasPublicationYear "2018" @default.
• W2894594324 type Work @default.
• W2894594324 sameAs 2894594324 @default.
• W2894594324 citedByCount "24" @default.
• W2894594324 countsByYear W28945943242019 @default.
• W2894594324 countsByYear W28945943242020 @default.
• W2894594324 countsByYear W28945943242021 @default.
• W2894594324 countsByYear W28945943242022 @default.
• W2894594324 countsByYear W28945943242023 @default.
• W2894594324 crossrefType "journal-article" @default.
• W2894594324 hasAuthorship W2894594324A5001001811 @default.
• W2894594324 hasAuthorship W2894594324A5004499685 @default.
• W2894594324 hasAuthorship W2894594324A5008873914 @default.
• W2894594324 hasAuthorship W2894594324A5011802071 @default.
• W2894594324 hasAuthorship W2894594324A5021072194 @default.
• W2894594324 hasAuthorship W2894594324A5028623947 @default.
• W2894594324 hasAuthorship W2894594324A5032537143 @default.
• W2894594324 hasAuthorship W2894594324A5036008316 @default.
• W2894594324 hasAuthorship W2894594324A5044154502 @default.
• W2894594324 hasAuthorship W2894594324A5049445389 @default.
• W2894594324 hasAuthorship W2894594324A5053002960 @default.
• W2894594324 hasAuthorship W2894594324A5064059340 @default.
• W2894594324 hasAuthorship W2894594324A5066921588 @default.
• W2894594324 hasAuthorship W2894594324A5071430390 @default.
• W2894594324 hasAuthorship W2894594324A5073230151 @default.
• W2894594324 hasAuthorship W2894594324A5075514097 @default.
• W2894594324 hasAuthorship W2894594324A5075894817 @default.
• W2894594324 hasAuthorship W2894594324A5077316104 @default.
• W2894594324 hasAuthorship W2894594324A5079691093 @default.
• W2894594324 hasAuthorship W2894594324A5081010890 @default.
• W2894594324 hasAuthorship W2894594324A5088223126 @default.
• W2894594324 hasAuthorship W2894594324A5088980190 @default.
• W2894594324 hasBestOaLocation W28945943241 @default.
• W2894594324 hasConcept C118552586 @default.
• W2894594324 hasConcept C126322002 @default.
• W2894594324 hasConcept C187212893 @default.
• W2894594324 hasConcept C2775858608 @default.
• W2894594324 hasConcept C2778186239 @default.
• W2894594324 hasConcept C2778715236 @default.
• W2894594324 hasConcept C2778980267 @default.

• next